Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

  • Contact

    1177 Avenue of the Americas
    5th Floor, Suite 5066
    New YorkNY10036
    USA

    T: +1 646 756-2997

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.5011.400.12%
CAC 408,347.2011.56-0.14%
DAX 4025,420.6615.320.06%
Dow JONES (US)49,279.18311.02-0.63%
FTSE 10010,137.353.35-0.03%
HKSE26,848.47239.990.90%
NASDAQ23,675.8858.03-0.24%
Nikkei 22553,549.161,609.273.10%
NZX 50 Index13,656.0527.24-0.20%
S&P 5006,956.2820.99-0.30%
S&P/ASX 2008,808.5017.200.20%
SSE Composite Index4,138.7626.53-0.64%

Market Movers